Hamburgers, Ground Beef Inspection Flaws.
If you’ve got to have one, grind your own.
Medicynical note: Our food supply system is failing. Industrialized agriculture’s goal is profit not better nutrition–sound familiar?
Hamburgers, Ground Beef Inspection Flaws.
If you’ve got to have one, grind your own.
Medicynical note: Our food supply system is failing. Industrialized agriculture’s goal is profit not better nutrition–sound familiar?
Posted in General Cynicism
I’m shopping for a new vacuum cleaner and my head is spinning from the multitude of features, conflicting reviews, and range of costs. Adding insult to injury, the same high quality vacuum that costs over $600 here actually costs less by over $200 in Europe. (Google the cost of a Miele or Sebo in UK and here). Other than health care I have trouble thinking of something that costs less in Europe than here.
I’ve been told we, the U.S., have the most efficient marketplace in the world in the U.S. That competition will find the “right” price.
What my experience tells me is that marketplaces can be manipulated, even for something simple and mundane.
Imagine how easily we could be manipulated if the issue is more complicated; the costs are 100 times more’; and if you don’t fully understand the problem and the options. Maybe that’s part of our health care waste alluded to in the last post.
Any vacuum recommendations?
Posted in General Cynicism
Here is RAND on health care waste.
How do we rank on administrative costs?
Medicynical note: The article points out that between $100 billion and 300 billion can be saved from health costs by curbing administrative waste.
Operational Waste?
Medicynical note: O’Neill is right in his belief that we can cut costs with more efficiency. Now health care operates on a cost plus basis–there is no incentive to be efficient at any level. With change we can achieve substantial savings, but not 50% in my view.
Clinical Waste:
Medicynical Note: Many interventions are simply ineffective or cost too much for very limited benefit. We, both the consumer and the health care providers, need help in deciding the proper course. Comparison studies are essential to health care reform. One would think that everyone would favor finding our what works better, but guess who opposes this? Amazing!
See the article for references and full explanations.
Posted in General Cynicism, Health Economics
This has been widely reported. Census data show falling income — latimes.com
Among other facts:
Medicynical Note: Meanwhile health care cost inflation is estimated at approaching 10% for 2009 by Price Waterhouse.
I don’t like anecdotes but it seems to be the currency of the debate on health care. So………
Case 1:
While at a local tumor board this week we encountered the case of a young woman with Hodgkin’s disease, a curable lymphoma. It’s curability depends in part on the stage of the disease–early is better than late. In this case the patient delayed calling attention to the mass in her neck for six months because she had no health insurance.
If Hodgkins disease is local, that is one or two lymph node areas involved, it can be treated with irradiation alone, i.e. without chemotherapy. The further advanced the disease the more extensive, expensive and toxic the treatment. Chemotherapy is necessary for most cases when the disease advances.
So this young woman went from have a disease amenable to local (extended field) irradiation to a situation where she will now require both systemic chemotherapy and irradiation. In addition to the immediate toxicity, her future fertility will likely be compromised–as well as her chance for cure. Guess who’s paying?
Case 2
This is the story of a young woman with headaches who earlier this summer delayed seeing a doctor because she had no insurance. The headaches persisted and while on a hike with a friend in the mountains, she collapsed and died. She undoubtedly had a leaking aneurysm which finally burst. Delay in seeking care in this case was fatal.
These are two cases from my personal experience in the last 3 months. Only in America would this be allowed to happen and only in America would people call such a dysfuntional non-systematic health care establishment the “best in the world.”
We need health reform to assure access to care. It’s literally killing us!
Posted in General Cynicism, Health Economics
If I understand it, the people who think health care reform will result in government control over a patient’s health care decisions, want the government to forbid people from choosing whether or not to have an abortion.
What’s going on here?
Posted in General Cynicism
That’s a deceptive title because when talking about a “free market” for products, there are many things “different” about the health care product.
I touched on a few in yesterday’s entry.
Today I’d like to explore the notion of effectiveness. In my specialty medical oncology, the only way we gauge effectiveness is through large studies of patients with the problem and comparing the outcomes (length of survival, rate of recurrence, etc). In any given patient it’s often difficult, if not impossible, to ascertain whether the treatment has actually worked or not.
For example, consider the patient with breast cancer who has had surgery with the tumor completely removed. If nothing else is done we will know in time whether the surgery cured the patient or not.
But, we often treat these patients with some type hormonal blocker (tamoxifen or another) with or without chemotherapy (called adjuvant therapy in doc talk). This can get quite expensive and is associated with frequent severe side effects.
If treated in this way and the tumor doesn’t recur, in any individual case we cannot know whether the surgery removed it all or the ensuing hormone blocking and/or chemo had some effect. Furthermore, if the tumor does recur later we are unable to determine whether the treatments delayed the recurrence.
The same is true for all other cancer types. In an individual case we simply cannot know whether the therapy given was worth the pain, cost and side-effects, unless large comparison studies of treatments and their outcomes are done.
You can of course say well, if it doesn’t return who cares. But given that tumors often recur and that there are extreme side-effects and greatly decreased quality of life from treatment and yes extreme costs, it’s important to understand whether a therapy works and just how effective it is.
Now to the difference between health care and other products. We spend literally thousands of dollars on treatments for cancer. Single drugs can cost as much as $100,000/year–that’s more than the great majority of people earn in year. In most instances, in cases of advanced disease, the improvement in survival from these agents (take Senator Kennedy’s case for example) is limited, measured in days to a few months. We, our health care non-system spend literally hundreds of billions of dollars for treatment of just these cases.
Can you name another product in this cost range, bought in the free market, that may not work? or may work for only a few days or months? or if it does work costs hundreds of thousands of dollars?
Well, that’s the situation in health care. Our costs are untenable; Our outcomes difficult to measure; and the purveyors of these products don’t want to do comparison studies to figure out what works and how it actually does work.
We do need reform!
Posted in Ethics, General Cynicism, Health Economics
Last week the President met with financial leaders and proposed reform and regulation of their market. You would think after the hundreds of billions spent to keep them afloat after their meltdown that they would be receptive to anything that would decrease the risk of a recurrence. But no, in typical american fashion, they seem to bridle under the accusation that their problem was self inflicted, that it would happen again and that some type of restraint (regulation) was necessary.
In health care we see similar NIMBY traits. No one wants to give an inch. Insurers want to continue their profligate policies that guarantee profits but not access or quality. Providers fear the unknown and are the most vulnerable so they are wary of change. Patent holders (technology or pharmaceuticals) oppose change because it might infringe on their profits. Parenthetically all are afraid that their cost plus gravy train is jeopardized.
You would think with the hundreds of billions wasted yearly on health care the players would be receptive to proposals that would decrease costs and improve efficiency. But no, in typical american fashion, they seem to bridle under the accusation that their problem is self inflicted, that it will continue and/worsen in and oppose the notion that some type of reform (regulation) is essential for improvement.
In reality there is no “free market” in health care, nor, for that matter, is one possible. For example, our patent system offers long protection to new drug developers and guarantees their monopoly. Some free market, particularly when they charge thousands of dollars/month for a drug alone–which accrues over 12 months to more than the yearly average income! This is particularly aggravated by the fact that in health care there is no assured access to full information; optional approaches are not fully explained, understandable to the average person nor universally available; the buyer is under duress; and the providers charge whatever they wish without relation to true cost.
As a result we ration access (50 million uninsured) and care by cost. That’s our non-system.
It’s distressing to see what’s happening in our congress. Their timidity and responsiveness to the health care lobby quite depressing.
Posted in General Cynicism, Health Economics
This was in Bill Moyer’s Journal week of July 9. Wendall Potter, an executive at CIGNA, reveals the other worldly quality of health insurers decision makers; their insular goals–and they are not improving health care; and explains his motivation in giving the interview. Worth seeing.
Medicynic: It really is about the money–insurers, high salaries and profits. Amazingly our legislators seem reluctant to reform our non-system. The industry seems to have them in their pocket–I mean pocketbook. We’ll need to drag them kicking and screaming into change.
Powered by Zoundry Raven
Posted in General Cynicism, Health Economics
In an attempt to prevent recurrence of breast cancer, chemotherapy is given after surgery. This is known as adjuvant chemotherapy.
One of the standard adjuvant regimens is CMF (cyclophosphamide, methotrexate, and 5-FU). Compared to other adjuvant regimens the toxicity is moderate but all the drugs are given intravenously. About 15 years ago Roche developed capecitabine (Xeloda) an oral drug that is simply 5FU in oral form. The cost of this drug is several hundred times (yes you read that correctly) that of the intravenous drug but the thought apparently was that the drug would save visits to infusion centers, which are also expensive.
Now, as reported in NEJM there is evidence that the use of capecitabine is inferior to CMF as adjuvant treatment of breast cancer in women over age 65. Unfortunately it’s taken 15 years to find this out.
Medicynical note: This experience is yet another example of why we need to compare treatment regimens. It’s counter intuitive to argue against this notion unless you are a drug company. Or an insecure physician who’s ego can’t deal with another source of information, besides the bias offered by pharmaceutical companies.
Powered by Zoundry Raven
From Forbes:
“But many companies seem to be maximizing cancer profit instead. Big drug companies are making big money off smaller and smaller improvements in cancer care. Newfangled cancer drugs can cost $50,000 a year, and that doesn’t mean they will add a year to the patient’s life–you might spend $50,000 for a year and extend the patient’s life by only weeks.”
Regarding Avastin:
“The hope was that further studies of Avastin in other types of cancer or in earlier stages of the disease would show even greater survival benefits. But they haven’t. In several breast-cancer trials–including a new one being presented at the meeting this weekend–Avastin slowed the progression of disease but did not extend patient survival at all. But doctors still use the drug in treating breast cancer because they figure it helps symptoms, even if patients don’t live longer. Avastin costs up to $55,000 a year.”
More:
“Roche is also combining other expensive drugs with Avastin. One study at the meeting showed that adding Tarceva……. delayed by one month the median time it takes lung tumors to grow. “
Medicynical note: ONE MONTH delay for $50,000. Terrific.
Where is the value? Meanwhile the drumbeat of studies showing very limited improvement but very high costs continues.
Also regarding Avastin:
“Avastin failed to prevent colon cancer from recurring after surgery. In the first year of treatment, more patients who got Avastin remained free of detectable cancer. But after a year, the drug was stopped, and by the end of the study, the apparent initial benefit had faded completely.”
In fact most people who receive drugs after surgery have no risk at all for recurrence. For those with what’s called Duke’s C disease the risk of recurrence is about 35-40%. Treatment with chemotherapy with or without Avasatin decreases the risk of recurrence by 15%. That means 20-25% recur no matter what we do. That also means that around 80% of people receiving these drugs get no benefit at all from chemo (the 60% without risk of recurrence and the 20% who recur no matter what we do).
The costs of these type treatments are astronomical. The drug company’s hopes of having $50,000/year drugs used on all patients are deal busters. I can’t think of a better poster child for comparison studies than those cited above.
Powered by Zoundry Raven